Scarica l'app Stockscreener
65.13
1.70%
1.09
Dopo l'orario di chiusura:
65.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Recovery Signals Appearing in Halozyme Therapeutics Inc. ChartsEarly Entry Tips With Low Risk Zone Shared - 선데이타임즈
What makes Halozyme Therapeutics Inc. stock price move sharplyHigh Performance Equity Ideas - thegnnews.com
Halozyme up after guidance raise, Morgan Stanley upgrade - MSN
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72 - MSN
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2 - Insider Monkey
Halozyme stock price target raised to $56 by Goldman Sachs on IRA impact analysis - Investing.com Canada
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - sharewise.com
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $63.00 at JPMorgan Chase & Co. - MarketBeat
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Is Halozyme Therapeutics Inc. part of any ETF3x Gain Trade Candidates - thegnnews.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Leerink Partners Maintains Sell Rating on Halozyme with $51 Price Target - AInvest
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Why Have Halozyme Stocks Plummeted? - TipRanks
What Does the Market Think About Halozyme Therapeutics? - 富途牛牛
A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $75 to $91 - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2025 Earnings Call Transcript - Insider Monkey
Results: Halozyme Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - 富途牛牛
HC Wainwright Raises Price Target for Halozyme Therapeutics to $75 - AInvest
Halozyme raises 2025 revenue guidance to $1.355B amid accelerating royalty growth and new product catalysts - MSN
Halozyme Therapeutics’ Earnings Call Highlights Robust Growth - TipRanks
Halozyme Therapeutics Surges on 86.74% Volume Spike to $360M, 329th Market Activity as Royalty Revenue Drives 41% EBITDA Jump - AInvest
Halozyme Therapeutics 2025 Q2 Earnings Surpasses Expectations, Net Income Surges 77% - AInvest
Halozyme Therapeutics (HALO): A High-Conviction Buy as Royalty-Driven Growth Accelerates - AInvest
Halozyme Therapeutics Lifts Outlook As Royalties Climb Higher - Finimize
Halozyme (HALO) Surges on Upgraded Guidance and Increased Revenue - GuruFocus
HALO: JMP Securities Raises Price Target Despite Maintaining "Ma - GuruFocus
Halozyme up after guidance raise, Morgan Stanley upgrade (HALO) - Seeking Alpha
Halozyme Therapeutics: JMP Securities Raises PT to $91 from $78, Maintains Market Outperform - AInvest
Halozyme Therapeutics Guidance Upgrade Driven by Robust Royalty Revenue, Morgan Stanley Says - MarketScreener
HALO Analyst Rating: HC Wainwright Maintains 'Buy' and Raises Pr - GuruFocus
Morgan Stanley Upgrades Halozyme Therapeutics (HALO) to Overweig - GuruFocus
Halozyme Therapeutics 2025 Q2 Earnings Surpasses Expectations with Net Income Jumping 77.1% - AInvest
Morgan Stanley Upgrades Halozyme Therapeutics to Overweight From Equalweight, Raises Price Target to $75 From $62 - MarketScreener
Halozyme Sees Price Target Boost Amid Strong Q2 Performance: Analyst Increases Target to $75, Maintains Buy Rating - AInvest
Halozyme (HALO) Sees Price Target Boost Amid Strong Q2 Performan - GuruFocus
Halozyme Therapeutics: A Masterclass in Platform-Driven Royalty Growth and Strategic Scalability - AInvest
Halozyme Therapeutics Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
Halozyme Therapeutics: A High-Conviction Buy in the IP-Driven Biotech Revolution - AInvest
Halozyme (HALO) Reports Record Q2 Revenue and Boosts 2025 Guidan - GuruFocus
Halozyme's Q2 2025: Unpacking Contradictions in Patent Litigation, ENHANZE Impact, and Regulatory Challenges - AInvest
Why Halozyme Shares Are Moving Amid Strong Earnings - TipRanks
Halozyme (HALO) Receives Upgrade and Raised Price Target from Mo - GuruFocus
Halozyme Therapeutics stock price target raised to $91 by Citizens JMP - Investing.com Australia
Morgan Stanley upgrades Halozyme stock to Overweight on ORPHAN Cures Act - Investing.com Nigeria
Morgan Stanley upgrades Halozyme stock to Overweight on ORPHAN Cures Act By Investing.com - Investing.com South Africa
Halozyme Therapeutics: Q2 Earnings Snapshot - New Haven Register
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - GuruFocus
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):